Haleon PLC

Haleon PLC

HLN · LSE · Healthcare / Drug Manufacturers - Specialty & Generic

344.80GBX+3.60 (+1.06%)

Price History

Full chart

Market Stats

Previous Close341.20
Open341.80
Day Range340.50 – 346.00
52-Week Range315.68 – 407.84
Volume22.39M
Market Cap28.87B
P/E (TTM)18.24
Forward P/E15.58
EPS0.18
Dividend Yield2.22%
Beta0.24
50-Day Avg354.36
200-Day Avg361.02

About

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Brian James McNamara
  • Employees24.54K
  • HeadquartersThe Heights, Weybridge, United Kingdom, KT13 0NY, UK
  • Websitehttps://www.haleon.com

Leadership

  • Mr. Brian James McNamaraCEO & Executive Director · b. 1966
  • Ms. Dawn Amanda AllenCFO & Director · b. 1968
  • Ms. Claire DicksonChief Digital & Technology Officer
  • Ms. Joanne RussellHead of Investor Relations
  • Mr. Adrian Charles MorrisGeneral Counsel · b. 1967
  • Ms. Tamara Jane RogersChief Marketing Officer · b. 1968
  • Ms. Line De DeckerChief Human Resources Officer · b. 1974
  • Mr. Filippo LanziPresident of EMEA & LatAm
  • Mr. Keith ChoyPresident of Asia Pacific · b. 1969
  • Mr. Bjorn TimelinHead of Strategy

Financials

Income Statement

Currency: GBP2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.48B9.89B9.54B10.86B11.30B11.23B11.03B
Growth (%)-+16.65%-3.51%+13.76%+4.09%-0.61%-1.81%
Cost of Revenue3.68B3.98B3.60B4.13B4.55B4.41B3.89B
Gross Profit4.80B5.91B5.95B6.73B6.75B6.82B7.14B
Gross Margin56.63%59.75%62.34%61.97%59.70%60.75%64.77%
Operating Expense3.90B4.31B4.31B4.90B4.75B4.62B4.67B
Operating Income897.00M1.60B1.64B1.82B2.00B2.21B2.48B
Operating Margin10.58%16.15%17.16%16.81%17.66%19.64%22.44%
EBITDA1.80B2.19B2.21B2.68B2.67B2.68B2.85B
EBITDA Margin21.24%22.14%23.16%24.71%23.66%23.88%25.86%
Net Income655.00M1.15B1.39B1.06B1.05B1.44B1.67B
Net Income Margin7.72%11.58%14.56%9.76%9.28%12.84%15.11%
R&D292.00M304.00M257.00M300.00M311.00M298.00M315.00M
R&D as % of Total Revenue3.44%3.07%2.69%2.76%2.75%2.65%2.86%
Interest Expense22.00M20.00M14.00M282.00M414.00M404.00M340.00M
Interest Expense % of Total Revenue0.26%0.20%0.15%2.60%3.66%3.60%3.08%

Balance Sheet

Currency: GBP2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets35.71B34.13B34.45B34.81B34.05B34.31B32.63B
Total Liabilities8.30B7.91B7.97B18.36B17.33B18.09B16.15B
Total Equity27.32B26.11B26.36B16.33B16.61B16.17B16.43B
Cash340.00M334.00M414.00M684.00M1.04B2.19B1.32B
Total Debt642.00M487.00M992.00M10.44B9.46B10.10B8.61B
Net Debt302.00M153.00M578.00M9.76B8.41B7.91B7.29B

Cash Flow

Currency: GBP2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow786.00M1.41B1.36B2.06B2.10B2.30B2.34B
Investing Cash Flow291.00M1.03B-33.00M-8.78B-134.00M528.00M-580.00M
Financing Cash Flow-925.00M-2.44B-1.24B6.91B-1.57B-1.54B-2.61B
Capital Expenditure243.00M318.00M298.00M328.00M336.00M318.00M322.00M
Free Cash Flow543.00M1.09B1.06B1.74B1.76B1.98B2.02B
Dividends Paid1.15B2.37B1.15B2.68B388.00M570.00M612.00M
FCF to OCF69.08%77.40%78.02%84.10%84.00%86.18%86.22%
Dividend Paid to FCF212.15%217.72%108.51%154.58%22.00%28.74%30.37%

Earnings

Report DateJun 6, 2022Sep 20, 2022Nov 10, 2022Mar 2, 2023May 3, 2023Aug 2, 2023Nov 2, 2023Feb 29, 2024May 1, 2024Aug 1, 2024Oct 31, 2024Feb 27, 2025Apr 30, 2025Jul 31, 2025Oct 30, 2025Dec 31, 2025Jun 30, 2026
EPS Estimate0.000.020.040.050.050.090.050.050.053.640.040.160.050.040.050.310.05
EPS Actual0.150.040.050.030.050.040.050.030.053.840.050.040.050.090.04--
Surprise-87.77%23.97%-32.60%-6.68%-61.64%9.13%-29.83%10.94%5.49%25.00%-75.00%0.00%115.31%-10.93%--
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-----

Key Statistics & Ratios

Market Cap28.87B
Enterprise Value37.53B
Trailing P/E18.24
Forward P/E15.58
PEG Ratio2.13
Price / Sales2.59
Price / Book1.84
EPS0.18
Book Value1.84
Revenue (TTM)11.15B
Gross Profit (TTM)7.31B
EBITDA2.85B
Profit Margin14.55%
Operating Margin23.94%
Return on Equity10.09%
Return on Assets5.08%
Shares Outstanding8.80B
Shares Float8.85B
Beta0.24
Dividend Yield2.22%
Dividend Rate0.07
Payout Ratio1.66%

Dividends

20262×
0.02Aug 13, 20260.05Apr 9, 2026
20252×
0.02Aug 14, 20250.05Apr 24, 2025
20242×
0.02Aug 15, 20240.04Mar 14, 2024
20232×
0.02Aug 24, 20230.02Mar 16, 2023